Workflow
Drug
icon
Search documents
These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth Builders
The Motley Fool· 2025-11-30 09:45
Group 1: Merck (MRK) - Merck is a pharmaceutical company facing specific risks, particularly related to patent cliffs where revenues can sharply decline after drug exclusivity ends [3][4] - The current market capitalization of Merck is $260 billion, with a current stock price of $104.83 and a dividend yield of 3.09% [5][6] - Merck's dividend payout ratio is approximately 50%, which is more sustainable compared to Pfizer's 90% payout ratio, positioning Merck better to maintain dividends despite upcoming patent cliffs [6] Group 2: Enbridge (ENB) - Enbridge operates a toll-taker business model, focusing on moving oil and natural gas, which makes it less sensitive to commodity price fluctuations [8][9] - The company has a market capitalization of $106 billion, with a current stock price of $48.78 and a dividend yield of 5.52% [10][11] - Enbridge has consistently increased its dividend annually for three decades, making it an attractive option for investors looking to enter the energy sector [11] Group 3: Bank of Nova Scotia (BNS) - Bank of Nova Scotia is currently undergoing a turnaround, focusing on North America and exiting less desirable operations in Central and South America [12][15] - The bank has a market capitalization of $86 billion, with a current stock price of $69.29 and a dividend yield of 4.44% [14][15] - The bank has a long history of paying dividends since 1833, indicating a commitment to returning value to shareholders [13]
International Markets and Perrigo (PRGO): A Deep Dive for Investors
ZACKS· 2025-08-11 14:15
Core Insights - The performance of Perrigo's international operations is critical for understanding its financial strength and growth potential [1][2][3] Group 1: International Revenue Performance - Perrigo's total revenue for the quarter was $1.06 billion, a decrease of 0.9% from the previous year [4] - Revenue from "All other countries" was $23.7 million, accounting for 2.2%, which was a surprise decrease of 14.75% compared to the expected $27.8 million [5] - Europe generated $421.7 million, constituting 39.9% of total revenue, exceeding the projected $398.44 million by 5.84% [6] Group 2: Future Revenue Forecasts - Analysts expect Perrigo to report total revenue of $1.12 billion in the current fiscal quarter, indicating a 3% increase from the prior year [7] - For the full year, total revenue is projected at $4.44 billion, reflecting a 1.6% increase from the previous year [8] Group 3: Market Context and Stock Performance - The company's reliance on international markets presents both opportunities and challenges, necessitating close monitoring of revenue trends [9] - Perrigo's stock has declined by 18.1% over the past month, contrasting with a 2.7% increase in the Zacks S&P 500 composite [13]